Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Anypodetos m (Restore title) |
blackwiki>Diannaa (improve mark-up) |
||
| Line 2: | Line 2: | ||
| name = Antithrombotics | | name = Antithrombotics | ||
| title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | | title = [[Antithrombotic]]s ([[thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) | ||
| − | |listclass = hlist | + | | listclass = hlist |
| − | + | | groupstyle = background:MistyRose; | |
| − | | groupstyle = background:MistyRose; | ||
| group1 = [[Antiplatelet drug]]s | | group1 = [[Antiplatelet drug]]s | ||
| Line 18: | Line 17: | ||
| group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | ||
| list2 = | | list2 = | ||
| − | * ''[[thienopyridine]]s'' | + | * ''[[thienopyridine]]s'' |
| − | * [[Prasugrel]] | + | ** [[Clopidogrel]] |
| − | * [[Ticlopidine]] | + | ** [[Prasugrel]] |
| − | * ''[[nucleotide]]/[[nucleoside]] analogs'' | + | ** [[Ticlopidine]] |
| − | * [[Elinogrel]] | + | * ''[[nucleotide]]/[[nucleoside]] analogs'' |
| − | * [[Ticagrelor]] | + | ** [[Cangrelor]] |
| + | ** [[Elinogrel]] | ||
| + | ** [[Ticagrelor]] | ||
| group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | ||
| Line 42: | Line 43: | ||
| group5 = [[Thromboxane inhibitors]] | | group5 = [[Thromboxane inhibitors]] | ||
| list5 = | | list5 = | ||
| − | * ''[[thromboxane synthase inhibitors]]'' | + | * ''[[thromboxane synthase inhibitors]]'' |
| − | * [[Picotamide]] | + | ** [[Dipyridamole]] |
| − | * ''[[Thromboxane receptor antagonist|receptor antagonist]]'' | + | ** [[Picotamide]] |
| + | |||
| + | * ''[[Thromboxane receptor antagonist|receptor antagonist]]'' | ||
| + | ** [[Terutroban]]<sup>†</sup> | ||
| group6 = [[Phosphodiesterase inhibitor]]s | | group6 = [[Phosphodiesterase inhibitor]]s | ||
| Line 52: | Line 56: | ||
* [[Triflusal]] | * [[Triflusal]] | ||
| − | | group7 = Other | + | | group7 = Other |
| list7 = | | list7 = | ||
* [[Cloricromen]] | * [[Cloricromen]] | ||
* [[Ditazole]] | * [[Ditazole]] | ||
| − | |||
}} | }} | ||
| Line 76: | Line 79: | ||
* [[Phenindione]] | * [[Phenindione]] | ||
| − | ''other:'' [[Tioclomarol]] | + | * ''other:'' [[Tioclomarol]] |
| group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | | group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | ||
| Line 84: | Line 87: | ||
| group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | ||
| list1 = | | list1 = | ||
| − | * ''[[low-molecular-weight heparin]]'' | + | * ''[[low-molecular-weight heparin]]'' |
| − | * [[Certoparin sodium|Certoparin]] | + | ** [[Bemiparin sodium|Bemiparin]] |
| − | * [[Dalteparin sodium|Dalteparin]] | + | ** [[Certoparin sodium|Certoparin]] |
| − | * [[Enoxaparin sodium|Enoxaparin]] | + | ** [[Dalteparin sodium|Dalteparin]] |
| − | * [[Nadroparin calcium|Nadroparin]] | + | ** [[Enoxaparin sodium|Enoxaparin]] |
| − | * [[Parnaparin sodium|Parnaparin]] | + | ** [[Nadroparin calcium|Nadroparin]] |
| − | * [[Reviparin sodium|Reviparin]] | + | ** [[Parnaparin sodium|Parnaparin]] |
| − | * [[Tinzaparin sodium|Tinzaparin]] | + | ** [[Reviparin sodium|Reviparin]] |
| + | ** [[Tinzaparin sodium|Tinzaparin]] | ||
| − | *''[[oligosaccharide]]s'' | + | * ''[[oligosaccharide]]s'' |
| − | * [[Idraparinux]] | + | ** [[Fondaparinux]] |
| + | ** [[Idraparinux]] | ||
| − | *''[[heparinoid]]'' | + | * ''[[heparinoid]]'' |
| − | * [[Sulodexide]] | + | ** [[Danaparoid]] |
| − | * [[Dermatan sulfate]] | + | ** [[Sulodexide]] |
| + | ** [[Dermatan sulfate]] | ||
| group7 = [[Direct Xa inhibitor]]s | | group7 = [[Direct Xa inhibitor]]s | ||
| list7 = | | list7 = | ||
| − | * ''xabans'' | + | * ''xabans'' |
| − | * [[Betrixaban]] | + | ** [[Apixaban]] |
| + | ** [[Betrixaban]] | ||
* [[Edoxaban]] | * [[Edoxaban]] | ||
| − | * [[Otamixaban]] | + | ** [[Otamixaban]] |
| − | * [[Rivaroxaban]] | + | ** [[Rivaroxaban]] |
| − | |||
}} | }} | ||
| group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s | | group6 = [[Direct thrombin inhibitor|Direct thrombin (II) inhibitor]]s | ||
| list6 = | | list6 = | ||
| − | * ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] | + | * ''[[Direct_thrombin_inhibitor#Bivalent|bivalent]]:'' [[Hirudin]] |
| − | * [[Lepirudin]] | + | ** [[Bivalirudin]] |
| − | * [[Desirudin]] | + | ** [[Lepirudin]] |
| + | ** [[Desirudin]] | ||
| − | *''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] | + | * ''[[Direct_thrombin_inhibitor#Univalent|univalent]]:'' [[Argatroban]] |
* [[Dabigatran]] | * [[Dabigatran]] | ||
* [[Melagatran]]<sup>‡</sup> | * [[Melagatran]]<sup>‡</sup> | ||
* [[Ximelagatran]]<sup>‡</sup> | * [[Ximelagatran]]<sup>‡</sup> | ||
| − | | group8 = Other | + | | group8 = Other |
| list8 = | | list8 = | ||
* [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | * [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | ||
| Line 127: | Line 134: | ||
* [[Ramatroban]] | * [[Ramatroban]] | ||
* [[Antithrombin|Antithrombin III]] | * [[Antithrombin|Antithrombin III]] | ||
| − | * [[Protein C]] | + | * [[Protein C]] |
| − | + | ** [[Drotrecogin alfa]] | |
}} | }} | ||
| group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | | group5 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | ||
| list5 = | | list5 = | ||
| − | * ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' | + | * ''[[plasminogen activator]]s:'' ''[[recombinant tissue plasminogen activators|r-tPA]]'' |
| − | * [[Reteplase]] | + | ** [[Tissue plasminogen activator|Alteplase]] |
| − | * [[Tenecteplase]] | + | ** [[Reteplase]] |
| − | * ''UPA'' | + | ** [[Tenecteplase]] |
| − | * [[Saruplase]] | + | * ''UPA'' |
| + | ** [[Urokinase]] | ||
| + | ** [[Saruplase]] | ||
* [[Streptokinase]]<sup>#</sup> | * [[Streptokinase]]<sup>#</sup> | ||
* [[Anistreplase]] | * [[Anistreplase]] | ||
| Line 145: | Line 154: | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
* [[Brinase]] | * [[Brinase]] | ||
| − | |||
| group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] | | group8 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] | ||
| Line 152: | Line 160: | ||
* [[EDTA]] | * [[EDTA]] | ||
* [[Oxalate]] | * [[Oxalate]] | ||
| − | |||
| − | |||
| − | |||
| belowstyle = background: transparent; padding: 0px; | | belowstyle = background: transparent; padding: 0px; | ||